Pyrazole Compounds Useful In The Treatment Of Inflammation
申请人:Nilsson Peter
公开号:US20070225318A1
公开(公告)日:2007-09-27
There is provided compounds of formula (I), wherein R
1
, R
2
, R
a
and R
b
have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.
There is provided compounds of formula I,
wherein R
1
, R
2
, X
1
, X
2
and n have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.
[EN] AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PARP1 À BASE D'AZÉTIDINE ET DE PYRROLIDINE ET LEURS UTILISATIONS
申请人:XINTHERA INC
公开号:WO2023056039A1
公开(公告)日:2023-04-06
Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
[EN] PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS<br/>[FR] DÉRIVÉS DE PHTALAZINE UTILISÉS COMME MODULATEURS DE LA PYRUVATE KINASE
申请人:[en]SITRYX THERAPEUTICS LIMITED
公开号:WO2023079294A1
公开(公告)日:2023-05-11
The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: wherein RA, RB, RCand RD, X, Y1, Y2, Y3, Z1, Z2and m are as defined herein.